REFRACTORY
Clinical trials for REFRACTORY explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY trials appear
Sign up with your email to follow new studies for REFRACTORY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New laser treatment aims to save sight in diabetic patients
Disease control Recruiting nowThis study tests a special laser (micropulse) to treat diabetic macular edema, a common cause of vision loss in people with diabetes. The trial will include 50 adults with diabetes who have central retinal swelling. Researchers will measure changes in vision and retinal thickness…
Matched conditions: REFRACTORY
Sponsor: The General Authority for Teaching Hospitals and Institutes • Aim: Disease control
Last updated May 17, 2026 03:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis study tests a new treatment for Hodgkin lymphoma that has returned or not responded to standard therapy. The treatment uses a patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a protein called CD30. About 31 participants will receive…
Matched conditions: REFRACTORY
Phase: PHASE1, PHASE2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC
-
Engineered immune cells take on lupus in first human trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called MC-1-50 for adults with severe lupus that hasn't responded to standard therapies. The treatment uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. The main goal is to check s…
Matched conditions: REFRACTORY
Phase: PHASE1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated May 07, 2026 18:42 UTC
-
Florida cancer study aims to speed up personalized treatment plans
Knowledge-focused Recruiting nowThis study is testing whether a new lab platform can quickly suggest personalized cancer treatments for 210 patients in Florida whose cancer has come back or not responded to standard therapy. The platform combines drug sensitivity testing and genetic profiling to recommend optio…
Matched conditions: REFRACTORY
Phase: NA • Sponsor: First Ascent Biomedical Inc. • Aim: Knowledge-focused
Last updated May 14, 2026 12:04 UTC